1. SYMPHONY: Results at 12 Months

2. Daclizumab Low dose CsA MMF Steroids B 50–100 ng/ml Low dose SRL D MMF Steroids Daclizumab 4-8 ng/ml Low dose TAC MMF Steroids Daclizumab 3-7 ng/ml C 150-300 ng/ml for 3 months 100-200 ng/ml thereafter Normal dose CsA MMF Steroids A SYMPHONY Study Design Tx 6 mo12 mo Adapted from Ekberg H. ATC 2007.

3. Renal Function-calculated GFR at month 12 (Cockcroft-Gault) ITT GFR (ml/min) nmedianmeanSD Normal-dose CsA Normal-dose CsA39057.057.125.1 Low-dose CsA Low-dose CsA39961.059.425.1 Low-dose TAC Low-dose TAC40166.265.427.0 Low-dose SRL Low-dose SRL39957.556.726.9 p<0.0001 p=0.0011 p<0.0001 Adapted from Ekberg H. ATC 2007.

4. Biopsy Proven Acute Rejection (ITT, Excluding Borderline) Probability of acute rejection Time (months) 25.8%Normal-dose CsA 24.0%Low-dose CsA 12.3%Low-dose TAC 37.2%Low-dose SRL 0.5 0.4 0.3 0.2 0.1 0.0 024681012 Adapted from Ekberg H. ATC 2007.

5. Graft and Patient Survival p=0.0147p=0.0143 89% 93% 94% 89% 70 80 90 100 12 months post-Tx Graft survival (%) 70 80 90 100 12 months post-Tx Patient survival (%) p = NS 96% 98% 97% Low-dose TAC Low-dose SRL Normal-dose CsA Low-dose CsA Adapted from Ekberg H. ATC 2007.

6. Results at 12 months post-Tx Calculated GFR (Cockcroft-Gault) 0 10 20 30 40 50 60 70 80 90 100 GFR (Cockcroft Gault) (ml/min) P<0.0001 P=0.0011 P<0.0001 57 59 65 57 Biopsy Proven Acute Rejection (ITT, Excluding Borderline) 26% 24% 12% 37% P<0.0001 0 10 20 30 40 50 BPAR (% of patients) Low-dose TAC Low-dose SRL Normal-dose CsA Low-dose CsA Adapted from Ekberg H. ATC 2007.